Ocumension Therapeutics
HKEX:1477

Watchlist Manager
Ocumension Therapeutics Logo
Ocumension Therapeutics
HKEX:1477
Watchlist
Price: 4.41 HKD 0.46%
Market Cap: 3.6B HKD
Have any thoughts about
Ocumension Therapeutics?
Write Note

Ocumension Therapeutics
Investor Relations

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Ye Liu
CEO & Executive Director
No Bio Available
Dr. Zhaopeng Hu
Chief Development Officer & Executive Director
No Bio Available
Mr. Tim Ruan
CFO & Joint Company Secretary
No Bio Available
Mr. Qinglei Zuo
Chief Commercial Officer
No Bio Available
Dr. NA NA
Chief Medical Officer
No Bio Available
Ms. Tingchan Chen
Joint Company Secretary
No Bio Available

Contacts

Address
JIANGSU
Suzhou
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District
Contacts